The Transmembrane Protease Serine 6 pipeline drugs market research report outlays comprehensive information on the Transmembrane Protease Serine 6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transmembrane Protease Serine 6 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Hematological Disorders, Oncology, Genetic Disorders, and Metabolic Disorders which include the indications Beta Thalassaemia, Thalassemia, Polycythemia Vera, Myelodysplastic Syndrome, Hemochromatosis, Primary (Inherited) Hemochromatosis, and Hypertriglyceridemia. It also reviews key players involved in Transmembrane Protease Serine 6 targeted therapeutics development with respective active and dormant or discontinued products.

The Transmembrane Protease Serine 6 pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 2, 2, and 6 respectively.

Transmembrane Protease Serine 6 overview

Transmembrane protease serine 6 (TMPRSS6) is a type II transmembrane serine proteinase that is found attached to the cell surface. Through the cleavage of cell surface HJV, a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis.

For a complete picture of Transmembrane Protease Serine 6’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.